Comparative Pharmacology
Head-to-head clinical analysis: AQUAPHYLLIN versus POLMON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUAPHYLLIN versus POLMON.
AQUAPHYLLIN vs POLMON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular cAMP and cGMP, leading to bronchodilation and anti-inflammatory effects.
Polmon (polymyxin B) is a cationic polypeptide antibiotic that disrupts bacterial cell membrane integrity by binding to lipopolysaccharides and phospholipids in the outer membrane, increasing permeability and causing cell death.
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
1-2 mg intravenously every 2-4 hours as needed; maximum 8 mg/day.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in severe hepatic impairment requiring dose adjustment.
Renal: 90-95% unchanged; biliary/fecal: <5%.
Renal excretion of unchanged drug accounts for 40-50% of elimination; biliary/fecal excretion accounts for 50-60%.
Category C
Category C
Bronchodilator
Bronchodilator